IBDEI1XM ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30861,1,3,0)
;;=3^Urinary Retention,Unspec
;;^UTILITY(U,$J,358.3,30861,1,4,0)
;;=4^R33.9
;;^UTILITY(U,$J,358.3,30861,2)
;;=^5019332
;;^UTILITY(U,$J,358.3,30862,0)
;;=I75.81^^123^1596^8
;;^UTILITY(U,$J,358.3,30862,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30862,1,3,0)
;;=3^Atheroembolism of Kidney
;;^UTILITY(U,$J,358.3,30862,1,4,0)
;;=4^I75.81
;;^UTILITY(U,$J,358.3,30862,2)
;;=^328516
;;^UTILITY(U,$J,358.3,30863,0)
;;=R34.^^123^1596^7
;;^UTILITY(U,$J,358.3,30863,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30863,1,3,0)
;;=3^Anuria and Oliguria
;;^UTILITY(U,$J,358.3,30863,1,4,0)
;;=4^R34.
;;^UTILITY(U,$J,358.3,30863,2)
;;=^5019333
;;^UTILITY(U,$J,358.3,30864,0)
;;=K76.7^^123^1596^9
;;^UTILITY(U,$J,358.3,30864,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30864,1,3,0)
;;=3^Hepatorenal Syndrome
;;^UTILITY(U,$J,358.3,30864,1,4,0)
;;=4^K76.7
;;^UTILITY(U,$J,358.3,30864,2)
;;=^56497
;;^UTILITY(U,$J,358.3,30865,0)
;;=N00.0^^123^1597^8
;;^UTILITY(U,$J,358.3,30865,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30865,1,3,0)
;;=3^Acute nephritic syndrome w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,30865,1,4,0)
;;=4^N00.0
;;^UTILITY(U,$J,358.3,30865,2)
;;=^5015491
;;^UTILITY(U,$J,358.3,30866,0)
;;=N00.1^^123^1597^7
;;^UTILITY(U,$J,358.3,30866,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30866,1,3,0)
;;=3^Acute nephritic syndrome w/ focal and segmental glomerular lesions
;;^UTILITY(U,$J,358.3,30866,1,4,0)
;;=4^N00.1
;;^UTILITY(U,$J,358.3,30866,2)
;;=^5015492
;;^UTILITY(U,$J,358.3,30867,0)
;;=N00.2^^123^1597^4
;;^UTILITY(U,$J,358.3,30867,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30867,1,3,0)
;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,30867,1,4,0)
;;=4^N00.2
;;^UTILITY(U,$J,358.3,30867,2)
;;=^5015493
;;^UTILITY(U,$J,358.3,30868,0)
;;=N00.3^^123^1597^5
;;^UTILITY(U,$J,358.3,30868,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30868,1,3,0)
;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30868,1,4,0)
;;=4^N00.3
;;^UTILITY(U,$J,358.3,30868,2)
;;=^5015494
;;^UTILITY(U,$J,358.3,30869,0)
;;=N00.4^^123^1597^3
;;^UTILITY(U,$J,358.3,30869,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30869,1,3,0)
;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30869,1,4,0)
;;=4^N00.4
;;^UTILITY(U,$J,358.3,30869,2)
;;=^5015495
;;^UTILITY(U,$J,358.3,30870,0)
;;=N00.5^^123^1597^6
;;^UTILITY(U,$J,358.3,30870,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30870,1,3,0)
;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,30870,1,4,0)
;;=4^N00.5
;;^UTILITY(U,$J,358.3,30870,2)
;;=^5015496
;;^UTILITY(U,$J,358.3,30871,0)
;;=N00.6^^123^1597^1
;;^UTILITY(U,$J,358.3,30871,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30871,1,3,0)
;;=3^Acute nephritic syndrome w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30871,1,4,0)
;;=4^N00.6
;;^UTILITY(U,$J,358.3,30871,2)
;;=^5015497
;;^UTILITY(U,$J,358.3,30872,0)
;;=N00.7^^123^1597^2
;;^UTILITY(U,$J,358.3,30872,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30872,1,3,0)
;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30872,1,4,0)
;;=4^N00.7
;;^UTILITY(U,$J,358.3,30872,2)
;;=^5015498
;;^UTILITY(U,$J,358.3,30873,0)
;;=N00.8^^123^1597^9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XM 3780 printed Sep 23, 2025@19:53:48 Page 2
IBDEI1XM ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30861,1,3,0)
+2 ;;=3^Urinary Retention,Unspec
+3 ;;^UTILITY(U,$J,358.3,30861,1,4,0)
+4 ;;=4^R33.9
+5 ;;^UTILITY(U,$J,358.3,30861,2)
+6 ;;=^5019332
+7 ;;^UTILITY(U,$J,358.3,30862,0)
+8 ;;=I75.81^^123^1596^8
+9 ;;^UTILITY(U,$J,358.3,30862,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,30862,1,3,0)
+12 ;;=3^Atheroembolism of Kidney
+13 ;;^UTILITY(U,$J,358.3,30862,1,4,0)
+14 ;;=4^I75.81
+15 ;;^UTILITY(U,$J,358.3,30862,2)
+16 ;;=^328516
+17 ;;^UTILITY(U,$J,358.3,30863,0)
+18 ;;=R34.^^123^1596^7
+19 ;;^UTILITY(U,$J,358.3,30863,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,30863,1,3,0)
+22 ;;=3^Anuria and Oliguria
+23 ;;^UTILITY(U,$J,358.3,30863,1,4,0)
+24 ;;=4^R34.
+25 ;;^UTILITY(U,$J,358.3,30863,2)
+26 ;;=^5019333
+27 ;;^UTILITY(U,$J,358.3,30864,0)
+28 ;;=K76.7^^123^1596^9
+29 ;;^UTILITY(U,$J,358.3,30864,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,30864,1,3,0)
+32 ;;=3^Hepatorenal Syndrome
+33 ;;^UTILITY(U,$J,358.3,30864,1,4,0)
+34 ;;=4^K76.7
+35 ;;^UTILITY(U,$J,358.3,30864,2)
+36 ;;=^56497
+37 ;;^UTILITY(U,$J,358.3,30865,0)
+38 ;;=N00.0^^123^1597^8
+39 ;;^UTILITY(U,$J,358.3,30865,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,30865,1,3,0)
+42 ;;=3^Acute nephritic syndrome w/ minor glomerular abnormality
+43 ;;^UTILITY(U,$J,358.3,30865,1,4,0)
+44 ;;=4^N00.0
+45 ;;^UTILITY(U,$J,358.3,30865,2)
+46 ;;=^5015491
+47 ;;^UTILITY(U,$J,358.3,30866,0)
+48 ;;=N00.1^^123^1597^7
+49 ;;^UTILITY(U,$J,358.3,30866,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,30866,1,3,0)
+52 ;;=3^Acute nephritic syndrome w/ focal and segmental glomerular lesions
+53 ;;^UTILITY(U,$J,358.3,30866,1,4,0)
+54 ;;=4^N00.1
+55 ;;^UTILITY(U,$J,358.3,30866,2)
+56 ;;=^5015492
+57 ;;^UTILITY(U,$J,358.3,30867,0)
+58 ;;=N00.2^^123^1597^4
+59 ;;^UTILITY(U,$J,358.3,30867,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,30867,1,3,0)
+62 ;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
+63 ;;^UTILITY(U,$J,358.3,30867,1,4,0)
+64 ;;=4^N00.2
+65 ;;^UTILITY(U,$J,358.3,30867,2)
+66 ;;=^5015493
+67 ;;^UTILITY(U,$J,358.3,30868,0)
+68 ;;=N00.3^^123^1597^5
+69 ;;^UTILITY(U,$J,358.3,30868,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,30868,1,3,0)
+72 ;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
+73 ;;^UTILITY(U,$J,358.3,30868,1,4,0)
+74 ;;=4^N00.3
+75 ;;^UTILITY(U,$J,358.3,30868,2)
+76 ;;=^5015494
+77 ;;^UTILITY(U,$J,358.3,30869,0)
+78 ;;=N00.4^^123^1597^3
+79 ;;^UTILITY(U,$J,358.3,30869,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,30869,1,3,0)
+82 ;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
+83 ;;^UTILITY(U,$J,358.3,30869,1,4,0)
+84 ;;=4^N00.4
+85 ;;^UTILITY(U,$J,358.3,30869,2)
+86 ;;=^5015495
+87 ;;^UTILITY(U,$J,358.3,30870,0)
+88 ;;=N00.5^^123^1597^6
+89 ;;^UTILITY(U,$J,358.3,30870,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,30870,1,3,0)
+92 ;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
+93 ;;^UTILITY(U,$J,358.3,30870,1,4,0)
+94 ;;=4^N00.5
+95 ;;^UTILITY(U,$J,358.3,30870,2)
+96 ;;=^5015496
+97 ;;^UTILITY(U,$J,358.3,30871,0)
+98 ;;=N00.6^^123^1597^1
+99 ;;^UTILITY(U,$J,358.3,30871,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,30871,1,3,0)
+102 ;;=3^Acute nephritic syndrome w/ dense deposit disease
+103 ;;^UTILITY(U,$J,358.3,30871,1,4,0)
+104 ;;=4^N00.6
+105 ;;^UTILITY(U,$J,358.3,30871,2)
+106 ;;=^5015497
+107 ;;^UTILITY(U,$J,358.3,30872,0)
+108 ;;=N00.7^^123^1597^2
+109 ;;^UTILITY(U,$J,358.3,30872,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,30872,1,3,0)
+112 ;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
+113 ;;^UTILITY(U,$J,358.3,30872,1,4,0)
+114 ;;=4^N00.7
+115 ;;^UTILITY(U,$J,358.3,30872,2)
+116 ;;=^5015498
+117 ;;^UTILITY(U,$J,358.3,30873,0)
+118 ;;=N00.8^^123^1597^9
